STIMUFEND® (pegfilgrastim-fpgk)

Update: 16 November, 2023

STIMUFEND®（pegfilgrastim-fpgk）is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

---

File format: PDF

Size: -

MD5 Checksum: 1004F290F0BC35EE14E5A52EE70F2D7D

Publication date: 16 November, 2023

Downloads: -

PDF Link: STIMUFEND® (pegfilgrastim-fpgk) PDF